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G protein-coupled receptor (GPR) 55 is sensitive to certain cannabi-
noids, it is expressed in the brain and, in cell cultures, it triggers
mobilization of intracellular Ca2+. However, the adaptive neurobio-
logical signiﬁcance of GPR55 remains unknown. Here, we use acute
hippocampal slices and combine two-photon excitation Ca2+ imag-
ing in presynaptic axonal boutons with optical quantal analysis in
postsynaptic dendritic spines to ﬁnd that GPR55 activation tran-
siently increases release probability at individual CA3-CA1 synapses.
The underlying mechanism involves Ca2+ release from presynaptic
Ca2+ stores, whereas postsynaptic stores (activated by spot-uncag-
ing of inositol 1,4,5-trisphosphate) remain unaffected by GPR55 ago-
nists. These effects are abolished by genetic deletion of GPR55 or by
the GPR55 antagonist cannabidiol, a constituent of Cannabis sativa.
GPR55 shows colocalization with synaptic vesicle protein vesicular
glutamate transporter 1 in stratum radiatum. Short-term potentia-
tion of CA3-CA1 transmission after a short train of stimuli reveals
a presynaptic, Ca2+ store-dependent component sensitive to canna-
bidiol. The underlying cascade involves synthesis of phospholipids,
likely in the presynaptic cell, but not the endocannabinoids 2-arach-
idonoylglycerol or anandamide. Our results thus unveil a signaling
role for GPR55 in synaptic circuits of the brain.
Endocannabinoids play a major regulatory role in the func-tioning of neural circuitry. Classically, they are discharged by
postsynaptic cells and target presynaptic cannabinoid type 1 (CB1)
receptors inhibiting neurotransmitter release (1, 2). Another
documented cannabinoid target, the CB2 receptor, is expressed
almost entirely outside the brain, and little is known about any
other cannabinoid signaling pathways. The cannabinoid-sensitive
receptor G protein-coupled receptor 55 (GPR55) was identiﬁed
and cloned a decade ago (3): Its presence in the brain, including
the hippocampus, has been shown using quantitative PCR (4, 5).
Although GPR55 activity can be modulated by certain phyto-
and endocannabinoids (4, 6), recent studies have suggested that
L-α-lysophosphatidylinositol (LPI), which activates GPR55 but
not CB1 or CB2 receptors, could be its endogenous ligand (7, 8).
Conversely, cannabidiol (CBD), a major constituent of Cannabis
sativa, is a GPR55 antagonist, with low afﬁnity for CB1 receptors
(4, 9). In cell cultures, activation of GPR55 evokes intracellular
Ca2+ oscillations through an inositol 1,4,5-trisphosphate (IP3)-
sensitive mechanism mobilizing Ca2+ stores (8, 10, 11) whereas
CBD can modulate neuronal Ca2+ depending on cell excitability
(12). However, the GPR55 pharmacology is enigmatic, and its
adaptive role in the brain remains unknown.
In the hippocampus, presynaptic Ca2+ stores contribute to re-
petitive release of glutamate (13, 14). Because GPR55 action has
been attributed to Ca2+ stores, we asked whether these receptors
inﬂuence transmission at CA3-CA1 synapses. To probe this
mechanism at the single-synapse level, we combine electrophysi-
ology with Ca2+ imaging in individual postsynaptic dendritic spines
(“optical quantal analysis”) and in presynaptic axons traced from
CA3 pyramidal cells into area CA1. We ﬁnd that activation of
GPR55 transiently increases release probability by elevating pre-
synaptic Ca2+ through the activation of local Ca2+ stores. We also
obtain evidence suggesting presynaptic expression of GPR55 and
its adaptive role in Ca2+-store–dependent short-term poten-
tiation of CA3-CA1 transmission. Finally, our data point to LPI
as a candidate endogenous ligand possibly released from pre-
synaptic axons. By revealing the adaptive neurophysiological role
of GPR55, these results also suggest a relevant neuronal target
for CBD.
Results
Activation of GPR55 Transiently Increases the Frequency of Miniature
Excitatory Postsynaptic Currents. Bath application of the GPR55
agonist LPI (4 μM here and throughout) in acute hippocampal
slices induced a prominent, 5- to 10-min boost in the frequency
of miniature excitatory postsynaptic currents (mEPSCs) recorded
in CA1 pyramidal cells (in 1 μM tetrodotoxin; average increase
over a 5-min interval after application 99 ± 25%, mean ± SEM
here and thereafter; P < 0.006, n = 8), with no effect on the
mEPSC waveform (Fig. 1A). The increase remained robust after
1 h of preincubation with the CB1 receptor antagonist AM281 at
500 nM (68 ± 10%, P < 0.003, n = 5; Fig. 1E; this AM281 ap-
plication protocol blocks the agonist action of WIN55,212-2; Fig.
S1 A and B). In contrast, the facilitatory effect of LPI was
abolished by the GPR55 antagonist CBD (1 μM; change 7 ± 4%,
n = 5; Fig. 1B). Because spontaneous release at CA3-CA1 syn-
apses partly depends on presynaptic Ca2+ stores (13), we asked
whether Ca2+ store depletion interferes with the GPR55 action.
The effect of LPI was abolished when Ca2+ stores were depleted
with 10 μM thapsigargin (n = 6) or 100 μM ryanodine (n = 6; Fig.
1E). In contrast, suppressing glial metabolism with ﬂuoroacetate
(FAC, 1-h incubation at 5 mM; ref. 15) did not abolish the LPI-
induced frequency increase (47 ± 11%, n = 5, P < 0.001; Fig.
1E). The GPR55 agonist O-1602 (100 nM here and throughout),
a structural analog of CBD with low afﬁnity for the CB1 or CB2
receptors (4), also increased the mEPSC frequency (by 118 ±
33%, n = 6, P < 0.017; Fig. 1C, tests in wild-type C57BL mice).
Importantly, the effects of either agonist were absent in the mice
lacking the GPR55 gene (Fig. 1 D and E). In contrast, Δ9tetra-
hydrocannabinol (Δ9THC) induced a small increase of the mEPSC
frequency in slices from both CB1 knockout (KO) and GPR55
KO mice (Fig. 1E), suggesting that Δ9THC may have residual
effects on multiple receptors. The undetectable effects of GPR55
agonists in KO animals were not due to the differences in average
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mEPSC rates, which were similar among the species (Fig. S1C).
Also, applying CBD at different time points after LPI did not
change the time course of facilitation (Fig. S1D), suggesting that
the latter is controlled downstream of GPR55 activation (e.g., by
a lasting Ca2+ discharge from stores).
Activation of GPR55 Transiently Potentiates Evoked CA3-CA1
Responses. Both LPI and O-1602 transiently increased EPSCs
or ﬁeld excitatory postsynaptic potentials (fEPSPs) evoked in
CA1 pyramids by stimulation of Schaffer collaterals. Again, Ca2+
store depletion with ryanodine, thapsigargin, or the IP3 receptor
blocker (-)-Xestospongin C (10 μM) abolished such increases, as
did CBD (Fig. 1G). Reassuringly, the effects of either GPR55
agonist were absent in GPR55 KO mice (Fig. 1G), whereas the
baseline probability of evoked release in these animals was
similar to that in wild type (WT; Fig. S1E). Overall, GPR55
agonists had a somewhat greater effect on spontaneous compared
with evoked responses (Fig. 1 E andG), possibly because mEPSCs
depend on Ca2+ store discharges more directly than do evoked
responses (13, 14).
Optical Quantal Analysis Establishes That GPR55 Activation Increases
Release Probability. Potentiation of evoked responses by GPR55
agonists was paralleled by a decreased paired-pulse ratio (PPR,
50-ms interval), suggesting an increase in release probability, Pr
(Fig. S2A). However, PPR is not always a reliable indicator of Pr
because it might also reﬂect changes in recruitment of activated
synapses (16). To gauge Pr more directly, we monitored Ca
2+ in
dendritic spines of CA1 pyramids (Fig. 2A) representing in-
dividual CA3-CA1 synapses. First, GPR55 agonists on their own
had no effect on Ca2+ inside the spine over ∼10 min of recording
(Fig. 2B) although these spines contained functional Ca2+ stores:
Two-photon spot uncaging of the Ca2+ store ligand IP3 inside the
spine head in a subset of experiments invariably evoked a Ca2+
rise characteristic of Ca2+ stores (17) (ΔG/R: 0.407 ± 0.050, n = 4,
P < 0.007; Fig. 2B). Postsynaptic Ca2+ stores were therefore in-
sensitive to GPR55 activation (Fig. 1 E and G). Second, we used
the optical quantal analysis (18, 19), which we adapted earlier
(20), to monitor individual evoked release events at CA3-CA1
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Fig. 1. Activation of GPR55 transiently boosts spontaneous and evoked CA3-
CA1 transmission. (A) LPI (4 μM throughout) increases mEPSC frequency in CA1
pyramids (four traces superimposed), with no effect on the waveform (Inset).
Plots are the average frequency (black) and amplitude (open) of mEPSCs
during LPI application. Error bars (throughout): SEM. (B) GPR55 antagonist CBD
(1 μM throughout) abolishes the effect of LPI. (C) GPR55 agonist O-1602 (100
nM throughout; C57BL mice) increases mEPSC frequency. (D) O-1602 has no
effect on mEPSCs in GPR55 KO mice. (E) Relative changes in mEPSC frequency
3–5 min after application, as indicated: LPI (n = 8); LPI + AM281 (0.5 μM, 1-h
incubation, n = 5), +CBD (n = 5), +ryanodine (+Rya, 100 μM throughout, n = 6),
thapsigargin (+Tha, 10 μM throughout; n = 6), or +4 mM ﬂuoroacetate (+FAC,
1-h incubation, n = 5); O-1602 in the wild-type mice (n = 6) and in GPR55 KO
(change –2 ± 3%, n = 7); LPI in GPR55 KO (change 3 ± 2%, n = 7), 4 μM Δ9THC
in CB1 KO mice (Δ9THC, change 21 ± 5%, n = 5), and in GPR55 KO mice (10 ±
1%, n = 5); white and gray columns: rats and mice, respectively, here and
thereafter. *P < 0.05; **P < 0.01; ***P < 0.005. (F) LPI transiently boosts
evoked CA3-CA1 transmission (EPSCs and fEPSP data combined). (Inset) fEPSP
example (black, baseline; red, averaged 3–5 min after application). Other no-
tation as in A–D. (G) Relative changes in the evoked response 3–5 min after
application, as indicated: LPI (EPSCs, n = 21, P < 0.001); LPI (fEPSPs, n = 7, P <
0.001); +Rya (n = 6), +Tha (n = 6), +10 μM (-)-Xestospongin C (+XeC, n = 5), and
CBD (change −1.1 ± 1.5%, n = 8); O-1602 in CBD (CBD+O-1602; change 0.4 ±
1.0%, n = 5), O-1602 in wild-type mice (n = 4, P < 0.05), and in GPR55 KO
(change 5 ± 6%, n = 4); and LPI in GPR55 KO (change 3 ± 2%, n = 9).
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Fig. 2. Activation of GPR55 increases release probability at individual CA3-
CA1 synapses. (A) Example of recorded CA1 pyramidal cell (Alexa channel);
stimulating pipette shown [stim; differential interference contrast (DIC)
channel, fragment]. (B Left) Dendritic fragment from the region indicated in
A; arrows, linescan position. (Center) LPI (4 μM) induces no Ca2+ changes in
the spine head (1 Hz linescan); one-cell example: arrows, linescan integration
segment. (Right) Uncaging IP3 (whole-cell, 400 μM; 10 5-ms pulses at 40 Hz,
λu2P = 720 nm, blue bar) inside the same spine induces a prominent Ca2+
signal (trace). (C) Dendritic fragment of interest (Left; arrows, linescan po-
sition) and linescan (Right; 500 Hz) in Alexa channel (“red” ﬂuorescence R).
(D) Linescans of the fragment shown in B in Fluo-4 channel. Paired stimuli
(dotted lines) induce four types of Ca2+ responses in one spine: 1 and 0,
success and failure, respectively; other notation as in B. (E Upper) Ca2+
ﬂuorescence time course (recorded as in D) before and after LPI application;
Arrows, stimulus onsets. (E Lower) Amplitudes of ﬁrst Ca2+ responses in the
same experiment. Blue shade, the range of failure (twice the baseline noise
SD). (F) Relative change in the Ca2+ ΔG/R amplitude (Upper) and Pr (Lower)
in response to: LPI (n = 5) and O-1602 (n = 4) in rats, O-1602 in wild type (n =
4), and LPI and O-1602 in GPR55 KO mice (n = 5 and n = 4, respectively).
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synapses (Fig. 2 C and E). By documenting successes and failures
of evoked Ca2+ rises in a postsynaptic dendritic spine, this ap-
proach provides direct readout of single-synapse Pr. Pr was in-
creased by both LPI (by 46 ± 12%, n = 5, P < 0.02) and O-1602
(by 35 ± 6% in the rat, n = 4, P < 0.009; and by 31 ± 6% in WT
mice, n = 4, P < 0.002) for 10–15 min after application, without
affecting the Ca2+ signal amplitude (Fig. 2 E and F and Fig. S2B).
Again, the effect of agonists was absent in the GPR55 KO mice
(change –5.1 ± 4.3%, n = 5, and –1.2 ± 5.3%, n = 4, respectively;
Fig. 2F and Fig. S2C).
GPR55 Receptors Engage Ca2+ Store Discharges in Individual Presynaptic
Boutons. Elevations of presynaptic Ca2+ is a classical mechanism
to control Pr. To monitor Ca
2+ in axonal boutons forming CA3-
CA1 synapses, we held CA3 pyramidal cells in whole-cell mode
and, in a number of fortuitous cases, traced the cell axon into
area CA1 (Fig. 3A), adapting identiﬁcation criteria established
by us previously (21). In all traced boutons, LPI induced
a prominent oscillatory elevation of Ca2+ lasting 5–15 min with
the average amplitude (ΔG/R: 0.175 ± 0.048, n = 5, P < 0.03)
comparable to spike-evoked Ca2+ entry in such boutons (ΔG/R:
0.118 ± 0.019, n = 7, P < 0.001; Fig. 3 B and E). O-1602 induced
a similarly long-lasting Ca2+ response in all recorded boutons
(ΔG/R: 0.082 ± 0.012, n = 5, P < 0.003; Fig. 3E and Fig. S3 A–
C). These elevations were abolished by ryanodine or thapsi-
gargin, which rapidly discharged Ca2+ stores upon application
(n = 5; Fig. 3 C and E and Fig. S3 D and E); at the same time,
however, LPI had no detectable inﬂuence on Ca2+ homeostasis
in CA1 astrocytes (Fig. S4). Similarly, 1 μM CBD suppressed the
effects of both LPI and O-1602 (applied ∼4 min after LPI; ΔG/R
0.000 ± 0.002, n = 4 traced axons; Fig. 3E). In contrast to GPR55
agonists, the CB1 receptor agonist WIN55,212-2 (500 nM) had
no effect on presynaptic Ca2+ (n = 7; Fig. 3E) although it could
robustly activate CB1 receptors (Fig. S1A). Again, in GPR55 KO
mice, LPI and O-1602 applied consecutively (∼4-min interval)
produced no elevation of presynaptic Ca2+ (ΔG/R 0.0016 ±
0.0011, n = 5; Fig. 3D), whereas spike-evoked Ca2+ entry
remained robust (ΔG/R 0.089 ± 0.013, n = 6; P < 0.001; Fig. 3 D
and E). These observations thus suggested that the GPR55-
induced increase in Pr (Fig. 2) involves discharges from pre-
synaptic Ca2+ stores.
GPR55 Is Expressed in Stratum Radiatum Showing Colocalization with
Synaptic Vesicles. To label GPR55 in acute slices we used an
Alexa Fluor 488 conjugated CTFL antibody (C terminus binding;
provided by Ken Mackie, Indiana University, Bloomington, IN;
Fig. 4A). Aiming at unbiased evaluation, we quasirandomly
sampled stratum radiatum and stratum pyramidale and applied
an unsupervised (blind) image segmentation algorithm for puncta
detection (Fig. 4B and SI Methods). WT samples showed pro-
foundly enhanced puncta labeling compared with GPR55 KO in
both hippocampal areas (Fig. 4C, magniﬁed in Fig. S5A). The
puncta density appeared lower than the occurrence of CA1-CA3
synapses (∼2 μm−3), suggesting a relatively low success rate of
epitope binding. To examine presynaptic location of GPR55, we
tested whether it was colocalized with the glutamatergic synaptic
vesicle protein vesicular glutamate transporter 1 (VGLUT1) (Fig.
4D). An image analysis algorithm that minimizes spurious coloc-
alization due to bleed-through, residual or background ﬂuores-
cence showed signiﬁcant colocalization compared with scrambled
images (Fig. 4 E and F and SI Methods), thus associating GPR55
expression with individual Schaffer collateral boutons (Fig. S6). In
addition, we tested GPR55 expression in presynaptic CA3 pyr-
amids by using a recently developed ﬂuorescent ligand, which has
a selectively high afﬁnity to GPR55, Tocriﬂuor T1117 (22). We
applied this water-soluble ligand extracelullarly by using a pressure
pipette placed near the CA3 pyramid (Alexa Fluor 488 was coe-
jected to monitor nonspeciﬁc uptake; Fig. S5B). Strikingly, cyto-
solic compartments of live CA3 pyramidal cells in slices from WT
and CB1 KO animals, but not GPR55 KO animals, readily accu-
mulated Tocriﬂuor T1117 (Fig. S5C).
Short-Term Postburst Synaptic Potentiation Has a GPR55-Dependent
Component.Although the above results relate GPR55 to enhanced
glutamate release and presynaptic Ca2+ stores, they do not reveal
whether this mechanism is engaged endogenously. Short bursts of
synaptic discharges transiently potentiate CA3-CA1 transmission,
which is thought to depend on presynaptic Ca2+ elevations (23).
We asked whether this type of postburst potentiation (PBP)
involves GPR55. We evoked PBP by applying 10 electric stimuli at
100 Hz to Schaffer collaterals, a protocol compatible with burst
activity of CA3 pyramids in situ (longer-term potentiation was
blocked with 50 μM (2R)-amino-5-phosphonovaleric acid, an
NMDA receptor antagonist). To examine the role of GPR55, PBP
was induced twice ∼20 min apart, and CBD was added shortly
after the ﬁrst induction. We found that CBD inhibited PBP sub-
stantially (in rats by 52 ± 15%, n = 5, P < 0.018; in WT mice by
63 ± 16%, n = 7, P < 0.009), whereas in control slices, with no
Tha LPI 
0.2
3 min 
C 
0.5 1.0 1.5 2.0 2.5 3.5 4.0 4.5 5.0 5.5 6.0 min  
OGB-1
Alexa
Tha 
300 ms 80 ms 
1 nA 
0.05
0.1
60 s 
Fluo-4Alexa
300 ms 
B 
Fluo-4
60 s 
LPI
D E
0.00
0.01
0.1
AP
G
P
R
55
 K
O
G
P
R
55
 K
O
LP
I+O
G
/R
LP
I+O
WI
N5
5
O-
16
02
+C
BD
+T
ha
/R
yaLP
I
AP
*
***
*** ** ***
0.05
50 ms 
spike 
GPR55 KO 
O-1602 
60 s 
LPI  
A 
CA3 
20 μm
CA1 
Alexa 
3 μm 
CA1 
CA3 DG 
Fig. 3. GPR55 activation prompts presynaptic Ca2+ elevation at CA3-CA1
synapses. (A) Tracing a CA3 pyramidal cell axon into CA1 (10–15 μm Kalman-
averaged stacks, collage). Bouton examples shown are magniﬁed. (Inset)
Experiment diagram. (B) An individual bouton [Upper Left; arrows, linescan
position) showing rapid spike-evoked Ca2+ entry (traces; Upper Center, 500
Hz linescan) and a slow LPI-induced Ca2+ elevation (Upper Right; 1 Hz line-
scan; black arrows, linescan region of interest (ROI)]. (B Lower) ΔG/R (Meth-
ods) time course. (C) CA1 presynaptic bouton seen in green (Upper) and red
(Lower) channels showing prominent Ca2+ rise induced by thapsigargin (Tha,
frame time points shown) but no effect of the subsequent LPI application
(Right; ΔG/R recording period extended). (D) In GPR55 KO, CA3-CA1 boutons
show robust spike-induced Ca2+ entry (Upper) but no response to LPI and
O-1602 (Lower); other notation as in B. (E) The average Ca2+ ΔG/R signal
evoked by: one action potential (AP, n = 7), LPI (n = 5), O-1602 (n = 5), LPI +
Tha or Rya (n = 5; average ΔG/R: 0.002 ± 0.006, combined data; difference with
the LPI-induced ΔG/R at P < 0.008), LPI followed by O-1602 (in ∼4 min) in CBD
(ΔG/R = 0.0015 ± 0.002, n = 4), and the CB1 receptor agonist WIN 55,212-2
(WIN55, n = 7; ΔG/R = 0.0015 ± 0.0019, n = 7, difference with the LPI-induced
signal at P < 0.005), LPI followed by O-1602 in wild-type mice (LPI+O, ΔG/R 0.10 ±
0.01, n = 5, P < 0.0012), and in GRR55 KO (ΔG/R 0.0016 ± 0.0011, n = 5), one
spike in GPR55 KO mice (AP in red, ΔG/R 0.089 ± 0.013, n = 6, P < 0.001).
Sylantyev et al. PNAS | March 26, 2013 | vol. 110 | no. 13 | 5195
N
EU
RO
SC
IE
N
CE
CBD application, PBP could be induced twice to the same level,
without rundown or enhancement (Fig. 5A and Fig. S7 A and B).
CBD was similarly active at 0.2 μM but, critically, it had no effect
on PBP in the GPR55 KO mice (Fig. 5 B and C, red arrow);
furthermore, baseline PBP in GPR55 KO was one-third of that in
the WT (11 ± 2% and 31 ± 6%; n = 7 and n = 6, respectively;
difference at P < 0.007). Again, PBP induction was not affected by
the CB1 receptors antagonist AM281 (500 nM; Fig. 5C), and
loading the postsynaptic cell with a Ca2+ chelating solution
[100 mM Cs-1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic
acid (BAPTA), whole-cell; Methods] had no effect on the CBD-
sensitive PBP component (Fig. 5C and Fig. S7C).
GPR55-Dependent Potentiation Requires Synthesis of Phospholipids
but Not Endocannabinoids. We next attempted to identify the
candidate endogenous ligand of GPR55, starting with the
endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG).
We incubated slices with 100 nM JNJ 1661010 or with either
20 nM or 1 μM URB-597 (inhibitors of fatty acid amide hydro-
lase) for 1 h to prevent anandamide hydrolysis. This application
had no effect on the CBD sensitivity of PBP (Fig. 5C and Fig. S7
D–F). We also blocked monoacylglycerol lipase, the enzyme in-
volved in hydrolysis of 2-AG, using N-arachidonyl maleimide
(NAM, 1 μM or 10 μM; 1 h), and blocked the production of
2-AG with the diacylglycerol lipase inhibitor, RHC 80267 (RHC,
10 μM) for 1 h. Again, this had no detectable effect on the CBD-
sensitive PBP (Fig. 5C and Fig. S7 G–I). Because LPI has been
suggested as an endogenous GPR55 agonist, we attempted to
suppress metabolic pathways that control synthesis of phospho-
lipids, by incubating slices for 1 h with YM 26734 (20 μM) and
arachidonyl triﬂuoromethyl ketone (AACOCF3) (10 μM), whichD E
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Fig. 4. Expression of GPR55 in area CA1 and its colocalization with synaptic
vesicle protein VGLUT1. (A) Experimental design for GPR55 immunolabeling
analyses: ﬁveWT and GPR55 KOmice samples; three slices in each animal; three
and quasirandomly selected ROIs (∼66 × 66 μm) in stratum radiatum and
stratum pyramidale. Two-way ANOVA design is shown (gene deletion and
hippocampal area being ﬁxed factors). (B Upper) Example of area CA1 labeled
for GPR55 in WT and GPR55 KO. Dotted rectangles, ROIs (higher resolution
shown in Fig. S5A). (B Lower) Outcome of blind image segmentation separat-
ing the puncta in the images above (Methods). (C) Relative area of puncta in
WT and KO. ***P < 0.001 (t test, n = 5 and n = 5) [ANOVA results: GPR55 gene-
speciﬁc puncta, P < 0.001 (F = 52.0); effect of region, P < 0.02 (F = 8.53);
“hippocampal region–gene deletion” interaction, P > 0.38 (F = 0.82)]. (D) Ex-
perimental design for GPR55-VGLUT1 colocalization analyses: fourWT and four
GPR55 KO mice; two slices in each stained for GPR55 and VGLUT1; and three
ROIs per slice. Diagram depicts pairs of original and “scrambled” ROIs analyzed
to obtain an unbiased colocalization indicator (SI Methods). (E) An example
stratum radiatum fragment labeled with GPR55 and VGLUT1 antibodies, seen
in several serial confocal sections 0.5 μm apart, as indicated. (F Left) Colocali-
zation index for WT and GPR55 KO samples (pixels from GPR55 and VGLUT1
channels that meet colocalization criteria minimizing bleed-through, back-
ground or residual ﬂuorescence; numbers relative to those in scrambled images
from WT, Scrmld; SI Methods); **P = 0.01 (three-way ANOVA nested, F = 34.1;
Methods); ***P < 0.003. (Right) Relative area of puncta in WT and KO, as in C,
in this sample, ***P < 0.005 (independent-sample t test).
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Fig. 5. PBP at CA3-CA1 synapses has a GPR55-dependent component. (A
Lower) Time course of PBP (fEPSP amplitude/slope monitored) induced twice
by 10 pulses at 100 Hz (arrows) in control (Left; n = 5) and test (Right, n = 5;
CBD application shown) groups of rats. (A Upper) Examples of baseline (black,
10 fEPSPs averaged) and potentiated (gray, ﬁrst fEPSP posttrain) responses;
CSP, CDB-sensitive PBP. (B) As in A but in GPR55 KO mice. (C) Results of
experiments similar to A and B, in different test conditions. Shown in the left
ordinate are the following: relative CSP in rats (n = 7; ***P < 0.001), WT C57
mice (WT, n = 6; **P < 0.0075), GPR55 KO (n = 7), with CBD applied at 0.2 μM
(n = 5; ***P < 0.003); with 100 mM Cs-BAPTA in whole-cell pipette (+BAPTA,
EPSC amplitudes, n = 5; ***P < 0.001), and after 1-h incubation with fatty acid
amide hydrolase inhibitors JNJ 1661010 (100 nM; +JNJ, n = 5; *P < 0.017),
URB-597 (0.02 and 1 μM; +URB 0.02 and +URB 1, respectively, n = 5, *P <
0.04), monoacylglycerol lipase inhibitor N-arachidonyl maleimide (1 and
10 μM; +NAM 1 and +NAM 10, respectively, n = 5; *P < 0.05, ***P < 0.005),
diacylglycerol lipase inhibitor RHC 80267 (10 μM, +RHC, n = 5, *P < 0.038),
and phospholipase A2 inhibitors YM 26734 and AACOCF3 applied together
(20 and 10 μM, respectively; +YM+AA, n = 5, P = 0.71; red arrow). Shown in
the right ordinate are the following: relative difference between the ﬁrst and
second PBP controls in rats (n = 10, P > 0.53), WT C57 mice (WT, n = 5, P >
0.33), and GPR55 KO mice (GPR55 KO, n = 5, P = 0.74); also showing PBP
sensitivity to 500 nM AM281 (+AM281, n = 5, P > 0.13), 10 μM thapsigargin
(+Tha, n = 5, ***P < 0.001), and 100 μM ryanodine (+Rya, n = 5, ***P < 0.001)
added after the ﬁrst PBP induction.
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inhibit phospholipase A2 (PLA2). Strikingly, this treatment did
abolish the CBD-sensitive PBP component (Fig. 5C, blue arrow;
and Fig. S7J). Finally, short-term PBP was completely blocked by
10 μM thapsigargin or by 100 μM ryanodine (Fig. 5C and Fig.
S8), thus conﬁrming the reliance of PBP on Ca2+ stores.
Short Spike Bursts Induce Slow Axonal Ca2+ Elevations Sensitive to
GPR55 and to Presynaptic Blockade of LPI Synthesis. To test whether
the CBD-sensitive PBP involves presynaptic Ca2+ changes, we
monitored Ca2+ signals evoked in axonal boutons of CA3 pyra-
midal cells (as in Fig. 3A) by 10 spikes at 100 Hz, before and after
application of CBD. In baseline conditions, the spike burst in-
duced not only a rapid Ca2+ increment reﬂecting spike-evoked
Ca2+ entry, but also a long (>80–90 s) oscillatory Ca2+ eleva-
tion (Fig. 6 A and B; Ca2+ monitoring beyond 1–2 min was un-
reliable because of issues pertinent to focus ﬂuctuations, pho-
tobleaching, and phototoxicity). Application of CBD inhibited
the slow Ca2+ signal component (by 57 ± 7% over 5–15 s after
burst, P < 0.001, n = 8), without affecting the initial rapid Ca2+
entry (Fig. 6B), thus implicating GPR55 into the PBP-dependent
presynaptic Ca2+ elevation. Strikingly, when we loaded the se-
lective PLA2 inhibitor AACOCF3 (10 μM) into the recorded
cell, the slow (but not fast) component of postburst Ca2+ elevation
was suppressed (from ΔG/R 0.037 ± 0.006 in control to 0.010 ±
0.003 with AACOCF3, P < 0.001, n = 8 and n = 6, respectively)
and it was insensitive to CBD (Fig. 6 C and D). Because in these
tests any signiﬁcant transmembrane escape of somatically
loaded AACOCF3 would prevent it from reaching the remote
axonal bouton at any effective level, this result associates the
CBD-sensitive presynaptic Ca2+ elevation with axonal release
of a candidate ligand (possibly LPI or a derivative).
LPI Induces Ca2+ Rises in Cultured Cell Axons Exposed to Bath
Medium. Although the ﬁndings above point to the role of pre-
synaptic GPR55, they do not rule out the involvement of GPR55
expressed in astroglia, which closely approach CA3-CA1 synapses
(24). To address this issue more directly, we monitored Ca2+ in
the axonal boutons of cultured hippocampal cells that are ex-
posed to the bath medium, with no glia present in the sur-
rounding environment (Fig. 6E, Left and Methods). Application
of LPI-induced robust oscillatory Ca2+ rises in such boutons, but
not in dendritic compartments of recorded cells (Fig. 6 E, Right,
and F). This result argues against the contribution of glia to
GPR55-dependent presynaptic Ca2+ elevations documented
here (although this ﬁnding does not exclude the expression and
physiological roles of astroglial GPR55 per se).
Discussion
Our results have unveiled an adaptive role for the enigmatic
cannabinoid-sensitive receptor GPR55 in the brain. Two struc-
turally dissimilar agonists (LPI and O-1602), which have differ-
ent target receptor pools overlapping at GPR55, prompted
transient increases in Pr at CA3-CA1 synapses, the phenomenon
conﬁrmed by using an “optical quantal analysis” of Ca2+ responses
in postsynaptic dendritic spines. The underlying mechanism
involves Ca2+-store dependent presynaptic Ca2+ elevations
recorded in axonal boutons traced from CA3 pyramids into area
CA1. Combination of pre- and postsynaptic Ca2+ imaging has
thus provided direct evidence for GPR55 function at the single-
synapse level, with the receptor identity validated by using
GPR55 KO animals. Interestingly, although the GPR55-dependent
presynaptic Ca2+ rise was comparable with the spike-evoked sig-
nal, it did not trigger neurotransmitter release. This result suggests
that the GPR55-activated Ca2+ source was further away from the
release machinery than spike-activated Ca2+ channels. We have
also obtained evidence for GPR55 expression in stratum radiatum,
also suggesting its submicron proximity to glutamatergic synaptic
vesicles expressing VGLUT1.
Previous work associated GPR55 actions with Gα12/13 G pro-
tein and RhoA-mediated, IP3-dependent Ca
2+ stores (8, 10, 11).
However, we have detected the role of both IP3 and non-IP3
stores. Indeed, various Ca2+ stores are thought to interact within
small axonal boutons, and further studies are needed to un-
derstand the interplay involved. Importantly, GPR55 could be
activated by physiologically relevant bursts of synaptic dis-
charges, thus contributing to short-term PBP of transmission.
Again, this involvement depends on presynaptic Ca2+ stores,
consistent with their role in use-dependent release enhancement
(14, 17). Our data report the transient nature of GPR55-induced
facilitation: This phenomenon might reﬂect the ﬁnite capacity, or
a relatively slow recharge rate, of Ca2+ stores triggered by GPR55
activation. Another possible explanation is internalization of ac-
tivated GPR55, which is possibly reﬂected in cellular uptake of
T1117 detected here.
GPR55 agonists did not activate functional postsynaptic Ca2+
stores, and postsynaptic Ca2+ chelation had no effect on the
GPR55-dependent PBP. These results argue against the post-
synaptic retrograde signaling involved in the observed Pr changes.
Similarly, GPR55 actions were insensitive to glial poisoning, and
GPR55 agonists had no effect on astrocytic Ca2+. Furthermore, in
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Fig. 6. Presynaptic Ca2+ rise is inhibited by CBD or by presynaptic suppres-
sion of PLA2 and can be induced in cultured cell axons with no glia in the
neighborhood. (A Left) Experiment diagram. (A Center) In example bouton
(Left, as in Fig. 3A), and its Ca2+ response to 10 spikes at 100 Hz (500 Hz
linescan, Fluo-8 channel) before (Upper) and 10 min after CBD application
(Lower). (A Right) Ca2+ responses expressed as ΔG/R. (B) Average Ca2+ re-
sponse to the 10-spike burst (onset t = 0) monitored in CA3-CA1 presynaptic
boutons for 80 s (n = 8) before (orange) and ∼20 min after (green) CBD
application. Averaging periods for the fast (0–2 s after burst) and slow (5–15 s)
Ca2+ elevations are shown. (C) Experiments as in B but with the phospholipid
synthesis inhibitor AACOCF3 (10 μM) in the cell (n = 6). (D) Effect of CBD on
fast (Upper) and slow (Lower) Ca2+ signals; ***P < 0.001. (E Left) A cultured
hippocampal neuron held in whole-cell (Inset, Alexa channel) with traced
axonal presynaptic boutons (merged with DIC image; postsynaptic dendrite
can be seen); arrows, linescan position. (Scale bar: 50 μm.) (E Right) (Upper)
Ca2+ signal in the bouton shown on the left, during bath application of 4 μM
LPI, as indicated. (Lower) Same Ca2+ response expressed as ΔG/R (Upper) and
in the dendrite from the same cell (Lower). (F) Effect of LPI on Ca2+ in axonal
boutons (n = 6; for comparison, typical spike-induced ΔG/R amplitude in
these axons were 0.13–0.15) and dendrites (n = 4) of recorded cells as in E;
***P < 0.001.
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hippocampal cultures, LPI evoked Ca2+ rises in axons exposed to
bath medium, with no glia present nearby. These data suggest little
role of astroglia in the observed phenomena (although they do not
rule out yet-unknown functions of glial GPR55, if such are pres-
ent). GPR55-dependent PBP remained intact when we interfered
with the metabolism of classical endocannabinoids 2-AG and
anandamide and was unaffected by inhibitors of the synthesis of
2AG. In contrast, inhibiting phospholipid synthesis blocked this
potentiation, consistent with LPI being an endogenous GPR55
agonist. Moreover, phospholipid synthesis blockade in the pre-
synaptic cell blocked the burst-evoked CBD-sensitive axonal
Ca2+ elevation. Although this result suggests an autoreceptor
mode for GPR55 during repetitive spiking, further studies are
needed to establish the exact source of the GPR55 ligand(s). It is
also an open question whether GPR55 acts at other synaptic
circuits. Finally, the ﬁnding that physiologically relevant GPR55
activation can be suppressed by CBD, a major constituent of
C. sativa, has potential implications for psychiatry. CBD has
a number of effects on humans, including antipsychotic and
antiepileptic (25). Our results suggest a GPR55-dependent
mechanism that may be involved in such effects. The facilitatory
effect of GPR55 contrasts the action of CB1 receptors that, if
anything, inhibit neurotransmitter release (1, 2). Δ9THC, a
major cannabis ingredient and a CB1 receptor agonist, has
variable effects on behavior depending on its dose (25, 26),
whereas use of cannabis with high Δ9THC and no CBD (“skunk”)
appears to increase risk of psychosis and memory impairment (27,
28). The present ﬁndings might help to understand the complex
neurobiological basis of such effects.
Methods
A brief description: The full details are given in SI Methods.
Preparation. Transverse 350-μmhippocampal slices were obtained from 3- to 4-
wk-old rats, 5- to 6-wk-old wild-type mice (CB57BL), age-matched GPR55 KO
mice (Gpr55tm1Lex, involves 129S/SvEvBrd × C57BL/6J) and CB1 KO mice (ABH
background; kindly supplied byDavid Baker (QueenMaryUniversity of London,
London) and Catherine Ledent, (Institut de Recherche Interdisciplinaire en
Biologie Humaine et Moleculaire, Brussels). Slices were transferred to the sub-
mersion recording chamber and superfused at 34 °C with oxygenated ACSF.
Recordings in hippocampal cultures were performed at 20- to 24-d in vitro at
34 °C, adapting described routine (29); electrophysiological and pharmacolog-
ical protocols were optimized for the corresponding tasks (SI Methods).
Imaging. Presynaptic CA3 or postsynaptic CA1 pyramidal cells were loaded in
whole-cell modewith Alexa 594 and a Ca2+ indicator (Fluo-4, Fluo-8, or OGB-1)
and examined by using a Radiance 2100 (Zeiss-Bio-Rad) based system as de-
scribed (17, 30). Evoked Ca2+ responses were routinely documented as ΔG/R
(18), where ΔG = G − G0 (the green channel signal G minus baseline ﬂuo-
rescence G0), and R stands for the Alexa channel ﬂuorescence.
Immunohistochemistry.We adapted the technique described (31): Slices were
repeatedly washed in PBS and incubated ﬁrst with the primary anti-GPR55
antibody (supplied by Ken Mackie) then with Alexa 488 conjugated Goat
anti-rabbit secondary antibody; in colocalization experiments also with pri-
mary anti-VGLUT1 antibody and Goat anti-Guinea Pig Alexa 568 secondary
antibody (SI Methods). Fluorescent puncta labeling was quantiﬁed by using
a blind threshold sliding ImageJ algorithm (Gabriel Lapointe, University of
Montreal, Montreal), and label colocalization was analyzed with an un-
supervised ImageJ colocalization algorithm (Pierre Bourdoncle, Universite
Paris Decartes, Paris). T1117 was applied in live slices near CA3 pyramids
through a pressurized pipette under constant monitoring (SI Methods).
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